1887
Volume 2014, Issue 2
  • ISSN: 2305-7823
  • E-ISSN:

Abstract

Major limitations of pulmonary arterial hypertension (PAH) drug trials include the small number of enrolled patients, short term follow up (12-16 weeks), and lack of morbidity and mortality primary endpoints. The recently published SERAPHIN (Study with an Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome) trial represents an important landmark in the history of clinical trials in PAH being the largest and longest clinical study conducted thus far in PAH patients with morbidity and mortality events as primary endpoint. SERAPHIN trial investigated whether long-term treatment with the new endothelin receptor antagonist macitentan would reduce the risk of mortality and morbidity in PAH patients.

Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2014.20
2014-09-01
2019-10-16
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2014/2/gcsp.2014.20.html?itemId=/content/journals/10.5339/gcsp.2014.20&mimeType=html&fmt=ahah

References

  1. [1]. Humbert   M., , Segal   ES., , Kiely   DG., , Carlsen   J., , Schwierin   B., , Hoeper   MM. . Results of European post-marketing surveillance of bosentan in pulmonary hypertension. . Eur Respir J . 2007; ;30: : 338– 344 .
    [Google Scholar]
  2. [2]. Paul   GA., , Gibbs   JS., , Boobis   AR., , Abbas   A., , Wilkins   MR. . Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. . Br J Clin Pharmacol . 2005; ;60: : 107– 112 .
    [Google Scholar]
  3. [3]. Burgess   G., , Hoogkamer   H., , Collings   L., , Dingemanse   J. . Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. . Eur J Clin Pharmacol . 2008; ;64: : 43– 50 .
    [Google Scholar]
  4. [4]. Pulido   T., , Adzerikho   I., , Channick   RN., , Delcroix   M., , Galiè   N., , Ghofrani   HA., , Jansa   P., , Jing   ZC., , Le Brun   FO., , Mehta   S., , Mittelholzer   CM., , Perchenet   L., , Sastry   BK., , Sitbon   O., , Souza   R., , Torbicki   A., , Zeng   X., , Rubin   LJ., , Simonneau   G., , SERAPHIN Investigators. . Macitentan and morbidity and mortality in pulmonary arterial hypertension. . New Engl J Med . 2013; ;369: : 809– 818 .
    [Google Scholar]
  5. [5]. Iglarz   M., , Binkert   C., , Morrison   K., , Fischli   W., , Gatfield   J., , Treiber   A., , Weller   T., , Bolli   MH., , Boss   C., , Buchmann   S., , Capeleto   B., , Hess   P., , Qiu   C., , Clozel   M. . Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. . J Pharmacol Exp Ther . 2008; ;327: : 736– 745 .
    [Google Scholar]
  6. [6]. Gatfield   J., , Mueller Grandjean   C., , Sasse   T., , Clozel   M., , Nayler   O. . Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. . PLoS One . 2012; ;7: : e47662 .
    [Google Scholar]
  7. [7]. Bruderer   S., , Hopfgartner   G., , Seiberling   M., , Wank   J., , Sidharta   PN., , Treiber   A., , Dingemanse   J. . Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. . Xenobiotica . 2012; ;42: : 901– 910 .
    [Google Scholar]
  8. [8]. Bruderer   S., , Aänismaa   P., , Homery   MC., , Häusler   S., , Landskroner   K., , Sidharta   PN., , Treiber   A., , Dingemanse   J. . Effect of cyclosporine A and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist. . AAPS J . 2012; ;14: : 68– 78 .
    [Google Scholar]
  9. [9]. Savarese   G., , Paolillo   S., , Costanzo   P., , D'Amore   C., , Cecere   M., , Losco   T., , Musella   F., , Gargiulo   P., , Marciano   C., , Perrone-Filardi   P. . Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. . J Am Coll Cardiol . 2012; ;60: : 1192– 1201 .
    [Google Scholar]
  10. [10]. Frost   AE., , Langleben   D., , Oudiz   R., , Hill   N., , Horn   E., , McLaughlin   V., , Robbins   IM., , Shapiro   S., , Tapson   VF., , Zwicke   D., , DeMarco   T., , Schilz   R., , Rubenfire   M., , Barst   RJ. . The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. . Vascul Pharmacol . 2005; ;43: : 36– 39 .
    [Google Scholar]
  11. [11]. Snow   JL., , Kawut   SM. . Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy. . Clin Chest Med . 2007; ;28: : 75– 89 .
    [Google Scholar]
  12. [12]. McLaughlin   VV., , Badesch   DB., , Delcroix   M., , Fleming   TR., , Gaine   SP., , Galiè   N., , Gibbs   JS., , Kim   NH., , Oudiz   RJ., , Peacock   A., , Provencher   S., , Sitbon   O., , Tapson   VF., , Seeger   W. . Endpoints and clinical trial design in pulmonary arterial hypertension. . J Am Coll Cardiol . 2009; ;54: Suppl 1 : S97– S107 .
    [Google Scholar]
  13. [13]. Gomberg-Maitland   M., , Bull   TM., , Saggar   R., , Barst   RJ., , Elgazayerly   A., , Fleming   TR., , Grimminger   F., , Rainisio   M., , Stewart   DJ., , Stockbridge   N., , Ventura   C., , Ghofrani   AH., , Rubin   LJ. . New trial designs and potential therapies for pulmonary artery hypertension. . J Am Coll Cardiol . 2013; ;62: : D82– D91 .
    [Google Scholar]
  14. [14]. Gabler   NB., , French   B., , Strom   BL., , Palevsky   HI., , Taichman   DB., , Kawut   SM., , Halpern   SD. . Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. . Circulation . 2012; ;126: : 349– 356 .
    [Google Scholar]
  15. [15]. Galiè   N., , Hoeper   MM., , Humbert   M., , Torbicki   A., , Vachiery   JL., , Barbera   JA., , Beghetti   M., , Corris   P., , Gaine   S., , Gibbs   JS., , Gomez-Sanchez   MA., , Jondeau   G., , Klepetko   W., , Opitz   C., , Peacock   A., , Rubin   L., , Zellweger   M., , Simonneau   G., , ESC Committee for Practice Guidelines (CPG). . Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). . Eur Heart J . 2009; ;30: : 2493– 2537 .
    [Google Scholar]
  16. [16]. Fattinger   K., , Funk   C., , Pantze   M., , Weber   C., , Reichen   J., , Stieger   B., , Meier   PJ. . The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. . Clin Pharmcol Ther . 2001; ;69: : 223– 231 .
    [Google Scholar]
  17. [17]. Bolli   MH., , Boss   C., , Binkert   C., , Buchmann   S., , Bur   D., , Hess   P., , Iglarz   M., , Meyer   S., , Rein   J., , Rey   M., , Treiber   A., , Clozel   M., , Fischli   W., , Weller   T. . The discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N′-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist. . J Med Chem . 2012; ;55: : 7849– 7861 .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2014.20
Loading
  • Article Type: Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error